Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't

This article was originally published in RPM Report

Executive Summary

The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.

You may also be interested in...



The Business Case for Adherence: A Win for Pharma Is A Win For Patients

Low rates of patient adherence to medical therapy has been a persistent policy hurdle that has significant commercial implications for drug makers. The health reform debate taking place in Washington should include a solution to the problem-but pharma shouldn't take the lead.

MedPAC On Steroids: The Implications of a New Medicare Advisory Council

The creation of an independent health council to weigh in on Medicare reimbursement rates may be part of a final health reform bill. The idea has a number of implications for biopharma-good and bad.

Obamacare: The Politics of Health Care Reform Entering the Endgame

There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel